RxDoctor Payments Data

Nishant Koradia, MD

Interventional Cardiology · Erie, PANPI 1407039530

Payments from drug & device makers

$19,063in general payments, 2019–2025

Across 397 payments — averaging $48.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$6K
  • Edwards Lifesciences$3K
  • Abiomed$2K
  • Boston Scientific$1K
  • Medtronic$1K
  • Inari Medical, Inc.$973
  • plus $4K from 26 others

What the payments were for

  • Speaking & faculty fees$5,46029%
  • Travel & lodging$250%
  • Food & beverage$13,57871%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,063 in reported general payments places this provider in the 60th percentile of 281 interventional cardiology providers in Pennsylvania.

See all interventional cardiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$163,205
Medicare patients
652
Services billed
1,514

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan372$447,239
XareltoRivaroxaban350$329,072
CamzyosMavacamten39$315,472
EliquisApixaban258$262,546
Repatha SureclickEvolocumab195$193,939
FarxigaDapagliflozin Propanediol186$184,622
JardianceEmpagliflozin113$101,520
BrilintaTicagrelor38$38,911
Ranolazine ErRanolazine213$21,920
Praluent PenAlirocumab32$21,109
Metoprolol Succinate898$10,436
Repatha PushtronexEvolocumab16$9,908
Ezetimibe444$9,084
Atorvastatin Calcium790$8,777
Rosuvastatin Calcium300$5,397

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$302$447,239372 claims
Johnson & JohnsonXarelto$239$329,072350 claims
E.r. Squibb & Sons, L.L.C.Camzyos$592$315,47239 claims
PfizerEliquis$16$262,546258 claims
AstraZenecaFarxiga, Brilinta$29$223,532224 claims
Boehringer IngelheimJardiance$100$101,520113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 281 interventional cardiology providers in Pennsylvania.

Other interventional cardiology in Erie

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →